17,261 trials
Squamous Non-small Cell Lung Cancer
Primary: Phase 1b: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0 Participants
Type 1 Diabetes
Primary: Hepatic Glucose Production (Co-primary Outcome) — 2.0; 2.0; 2.1; 1.8 mg/kg-minute
Primary Mediastinal B-cell Lymphoma · Diffuse, Large B-cell Lymphoma · Diffuse Large B-Cell Lymphoma Transformed From Follicular Lymphoma
Primary: Number of Participants With a Response Assessed by the Response Criteria for Malignant Lymphoma — 2; 3; 2; 3 Participants
Cystic Fibrosis
Primary: Number of Participants With 5% or Greater Relative Change in FEV1 (Liters) From Baseline to Day 28 — 22; 17 Participants — p=0.811
Macular Edema
Primary: Change From Baseline in Central Subfield Foveal Thickness (CSFT) at Week 12 — -6.19; 10.26 Micrometre [μm] — p=0.3199
Head and Neck Neoplasms · Head and Neck Lymphedema · Head and Neck Cancer
Primary: Lymph Movement Measured by ICG Lymphography. — 5; 5; 0; 0 Participants
Prostate Cancer
Primary: Two Year Progression-free Survival — 64.9 percentage
Non Small Cell Lung Cancer
Primary: Progression Free Survival — 28 weeks
Cystic Fibrosis
Primary: AUC by Dose — 7699; 2342 pg*h/mL
Pancreatic Cancer · Pancreatic Adenocarcinoma
Primary: MK-0646 Maximum Tolerable Dose — 0; 0; 0; 2 participants
BRCA1 Mutation Carrier · BRCA2 Mutation Carrier · Ovarian Epithelial Tumor
Primary: Proportion of Patients With Complete and Partial Tumor Response — 0.26 Proportion of patients
Ulcerative Colitis Associated Pouchitis
Primary: Number of Patients Who Experienced Improvement of Pouchitis Symptoms — 2 Participants
Non-Alcoholic Steatohepatitis
Primary: Number of Participants With Biopsy Proven Non-Alcoholic Steatohepatitis — 74; 20; 13 Participants
Obesity
Primary: Change in Oxidative Stress: Baseline to 2 Hours — -0.003; -0.006; 0.01; -0.006 pg /ml
Primary Sjögren's Syndrome
Primary: Change From Baseline in European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) Score at Day 99 — -2.3; -3.8 Scores on a scale — p=0.262